Sabirnetug

N/A

Report date: 2024/11/04 16:57:00

Base Information

Drug NameSabirnetug
Drug Alias NameAnti-Amyloid Beta Oligomer Antibody (Acumen Pharmaceuticals )ACU-193ACU193HuC-091
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAmyloid protein aggregation inhibitorsAmyloid antagonists
TargetsAmyloid
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNorthwestern University
China Registration ClassN/A

Develop Information

Active CompaniesLonzaAcumen Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A